keyword
MENU ▼
Read by QxMD icon Read
search

Myeloma multiple 2016

keyword
https://www.readbyqxmd.com/read/29996124/leptomeningeal-myelomatosis-a-rare-but-devastating-manifestation-of-multiple-myeloma-diagnosed-using-cytology-flow-cytometry-and-fluorescent-in-situ-hybridization
#1
Martin Bommer, Miriam Kull, Veronica Teleanu, Phyllis Schwarzwälder, Manuela Feuring-Buske, Jan Kroenke, Donald Bunjes, Christian Langer
INTRODUCTION: Involvement of the central nervous system in patients with multiple myeloma is a rare event. We evaluated the diagnostic workup and prognosis of patients with leptomeningeal myelomatosis (LMM). METHODS: Between April 2005 and April 2016, we identified 16 cases with LMM. The involvement was diagnosed by magnetic resonance imaging (MRI), cerebrospinal fluid (CSF) cytology as well as flow cytometry. Fluorescence in situ hybridization (FISH) was used in 8/16 cases...
July 11, 2018: Acta Haematologica
https://www.readbyqxmd.com/read/29986853/impact-of-post-asct-maintenance-therapy-on-outcomes-in-patients-with-newly-diagnosed-multiple-myeloma-in-connect-mm
#2
Sundar Jagannath, Rafat Abonour, Brian G M Durie, Mohit Narang, Howard R Terebelo, Cristina J Gasparetto, Kathleen Toomey, James W Hardin, Lynne Wagner, Amit Agarwal, Shankar Srinivasan, Amani Kitali, E Dawn Flick, Michael Sturniolo, Robert M Rifkin
Autologous stem cell transplantation (ASCT) followed by lenalidomide maintenance therapy is the standard of care for transplant-eligible patients with newly diagnosed multiple myeloma (NDMM). Clinical trials show progression-free survival (PFS) benefits, with some studies (Cancer and Leukemia Group [CALGB] trial and meta-analysis) also showing overall survival (OS) benefits, but applicability to real-world clinical settings is unclear. Using data from Connect MM, the largest US-based observational registry of NDMM patients, we analyzed effects of maintenance therapy on long-term outcomes in 1450 treated patients enrolled from 2009 to 2011...
July 10, 2018: Blood Advances
https://www.readbyqxmd.com/read/29950224/-bone-marrow-morphology-of-multiple-myeloma-with-non-bone-related-extramedullary-disease
#3
Di Wu, Wen-Juan Wang, Mei Zhang
OBJECTIVE: To explore the morphological characteristics of bone marrow cells of multiple myeloma with non-bone-related extramedullary disease and thier clinical significance. METHODS: Bone marrow smears, peripheral blood smears and bone marrow biopsy sections as well as thier examination results of 20 cases of multiple myloma with non-bone-related extramedullary disease were collected at initial diagnosis in First Affiliated Hospital of Xi'an Jiaotong University from March 2013 to March 2016, and morphological characterisistes of bone marrow cells were analysed in combination with clinical data...
June 2018: Zhongguo Shi Yan Xue Ye Xue za Zhi
https://www.readbyqxmd.com/read/29950223/-diagnostic-value-of-igf-i-%C3%AE-2-mg-and-sf-for-patients-with-multiple-myeloma-and-their-relationship-with-clinical-staging
#4
Xiao-Ying Wu, Ju-Mei Shi, Yi Tao, Zhong Li
OBJECTIVE: To investigate the diagnostic value of insulin like growth factor I(IGF-I), β2-microglobulin (β2MG) and serum ferritin (SF) in patients with multiple myeloma (MM) and their ralationship with clinical staging. METHODS: Seventy-seven patients with MM treated in Depertment of Hematology of Shanghai 10th hospital and Oncology of Shanghai Armed Police Hospital from August 2016 to June 2017 were enrolled in MM group, at same period 77 healthy volunteers were enrolled in normal control group...
June 2018: Zhongguo Shi Yan Xue Ye Xue za Zhi
https://www.readbyqxmd.com/read/29943829/adipokines-adiposity-and-bone-marrow-adipocytes-dangerous-accomplices-in-multiple-myeloma
#5
REVIEW
Emma V Morris, Claire M Edwards
Obesity has become a global epidemic influencing the establishment and progression of a wide range of diseases, such as diabetes, cardiovascular disease, and cancer. In 2016, International Agency for Research on Cancer reported that obesity is now associated with 13 different cancers, one of which is multiple myeloma (MM), a destructive cancer of plasma cells that predominantly reside in the bone marrow. Obesity is the accumulation of excess body fat, which causes metabolic, endocrine, immunologic, and inflammatory-like changes...
June 26, 2018: Journal of Cellular Physiology
https://www.readbyqxmd.com/read/29890920/granulocyte-colony-stimulating-factor-utilization-postautologous-hematopoietic-stem-cell-transplant-in-multiple-myeloma-patients-does-one-size-fit-all
#6
Emily R Jackson, Jason R Jared, Jennifer K Piccolo, Kaitlin M Woo, Mary S Mably, Michael P Reed, Natalie S Callander
Purpose To evaluate a single institution's experience with granulocyte colony-stimulating factor after autologous hematopoietic stem cell transplant in myeloma patients to identify populations that benefit most from granulocyte colony-stimulating factor administration. Methods Retrospective chart reviews were conducted on patients 18+ years with multiple myeloma that underwent autologous hematopoietic stem cell transplant at UW Health from January 2012 to May 2016. Data collection included demographics, length of stay, time to engraftment, Eastern Cooperative Oncology Group performance status score, and hematopoietic cell transplantation-comorbidity index...
January 1, 2018: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/29866475/once-weekly-versus-twice-weekly-carfilzomib-dosing-in-patients-with-relapsed-and-refractory-multiple-myeloma-a-r-r-o-w-interim-analysis-results-of-a-randomised-phase-3-study
#7
Philippe Moreau, Maria-Victoria Mateos, James R Berenson, Katja Weisel, Antonio Lazzaro, Kevin Song, Meletios A Dimopoulos, Mei Huang, Anita Zahlten-Kumeli, A Keith Stewart
BACKGROUND: Twice a week carfilzomib at 27 mg/m2 is approved for treatment of relapsed or refractory multiple myeloma. Phase 1/2 CHAMPION-1, the first study exploring once-weekly carfilzomib dosing, established the maximum tolerated dose at 70 mg/m2 in combination with dexamethasone. We aimed to compare progression-free survival in patients with relapsed and refractory multiple myeloma given once weekly carfilzomib or twice weekly carfilzomib. METHODS: In this prespecified interim analysis of the randomised, open-label, phase 3 A...
May 31, 2018: Lancet Oncology
https://www.readbyqxmd.com/read/29844008/heterogeneity-of-second-line-treatment-for-patients-with-multiple-myeloma-in-the-connect-mm-registry-2010-2016
#8
Sundar Jagannath, Rafat Abonour, Brian G M Durie, Cristina Gasparetto, James W Hardin, Mohit Narang, Howard R Terebelo, Kathleen Toomey, Lynne Wagner, Shankar Srinivasan, Amani Kitali, Lihua Yue, E Dawn Flick, Amit Agarwal, Robert M Rifkin
BACKGROUND: The treatment landscape for multiple myeloma (MM) has undergone recent changes with the regulatory approval of several new therapies indicated for second- and later-line disease. Using data from Connect MM, the largest multisite, primarily community-based, prospective, observational registry of MM patients in the United States, selection of second-line treatments was evaluated during a 5-year period from 2010 to 2016. PATIENTS AND METHODS: Eligible patients were aged ≥ 18 years, had newly diagnosed MM ≤ 2 months before study entry, and were followed for up to 8 years...
July 2018: Clinical Lymphoma, Myeloma & Leukemia
https://www.readbyqxmd.com/read/29808907/elotuzumab-monotherapy-in-patients-with-smouldering-multiple-myeloma-a-phase-2-study
#9
Sundar Jagannath, Jacob Laubach, Ellice Wong, Keith Stockerl-Goldstein, Cara Rosenbaum, Madhav Dhodapkar, Ying-Ming Jou, Mark Lynch, Michael Robbins, Suresh Shelat, Kenneth C Anderson, Paul G Richardson
Smouldering multiple myeloma (SMM) is associated with increased risk of progression to multiple myeloma within 2 years, with no approved treatments. Elotuzumab has been shown to promote natural killer (NK) cell stimulation and antibody-dependent cellular cytotoxicity (ADCC) in vitro. CD56dim (CD56dim /CD16+ /CD3- /CD45+ ) NK cells represent the primary subset responsible for elotuzumab-induced ADCC. In this phase II, non-randomized study (NCT01441973), patients with SMM received elotuzumab 20 mg/kg intravenously (cycle 1: days 1, 8; monthly thereafter) or 10 mg/kg (cycles 1, 2: weekly; every 2 weeks thereafter)...
May 29, 2018: British Journal of Haematology
https://www.readbyqxmd.com/read/29800065/global-burden-of-multiple-myeloma-a-systematic-analysis-for-the-global-burden-of-disease-study-2016
#10
Andrew J Cowan, Christine Allen, Aleksandra Barac, Huda Basaleem, Isabela Bensenor, Maria Paula Curado, Kyle Foreman, Rahul Gupta, James Harvey, H Dean Hosgood, Mihajlo Jakovljevic, Yousef Khader, Shai Linn, Deepesh Lad, Lorenzo Mantovani, Vuong Minh Nong, Ali Mokdad, Mohsen Naghavi, Maarten Postma, Gholamreza Roshandel, Katya Shackelford, Mekonnen Sisay, Cuong Tat Nguyen, Tung Thanh Tran, Bach Tran Xuan, Kingsley Nnanna Ukwaja, Stein Emil Vollset, Elisabete Weiderpass, Edward N Libby, Christina Fitzmaurice
Introduction: Multiple myeloma (MM) is a plasma cell neoplasm with substantial morbidity and mortality. A comprehensive description of the global burden of MM is needed to help direct health policy, resource allocation, research, and patient care. Objective: To describe the burden of MM and the availability of effective therapies for 21 world regions and 195 countries and territories from 1990 to 2016. Design and Setting: We report incidence, mortality, and disability-adjusted life-year (DALY) estimates from the Global Burden of Disease 2016 study...
May 16, 2018: JAMA Oncology
https://www.readbyqxmd.com/read/29795433/prevention-and-treatment-of-relapse-after-stem-cell-transplantation-in-lymphoid-malignancies
#11
Anna Sureda, Peter Dreger, Michael R Bishop, Nicolaus Kroger, David L Porter
Relapse is now the major cause of treatment failure after allogeneic HSCT (alloHSCT). Many novel strategies to address this critical issue are now being developed and tested. At the 3rd International Workshop on Biology, Prevention, and Treatment of Relapse held in Hamburg, Germany in November 2016, international experts presented and discussed recent developments in the field. Some approaches may be applicable to a wide range of patients after transplant, whereas some may be very disease-specific. We present a report from the session dedicated to issues related to prevention and treatment of relapse of lymphoid malignancies after alloHSCT...
May 24, 2018: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/29794238/efficacy-and-safety-of-percutaneous-microwave-ablation-and-cementoplasty-in-the-treatment-of-painful-spinal-metastases-and-myeloma
#12
M A Khan, G Deib, B Deldar, A M Patel, J S Barr
BACKGROUND AND PURPOSE: Painful spinal metastases are a common cause of cancer-related morbidity. Percutaneous ablation presents an attractive minimally invasive alternative to conventional therapies. We performed a retrospective review of 69 patients with 102 painful spinal metastases undergoing microwave ablation and cementoplasty to determine the efficacy and safety of this treatment. MATERIALS AND METHODS: Procedures were performed between January 2015 and October 2016 with the patient under general anesthesia using image guidance for 102 spinal metastases in 69 patients in the following areas: cervical ( n = 2), thoracic ( n = 50), lumbar ( n = 34), and sacral ( n = 16) spine...
July 2018: AJNR. American Journal of Neuroradiology
https://www.readbyqxmd.com/read/29781040/autologous-stem-cell-transplantation-in-first-remission-is-associated-with-better-progression-free-survival-in-multiple-myeloma
#13
Mukul Aggarwal, Narendra Agrawal, Neha Yadav, Priyanka Verma, Rayaz Ahmed, Pallavi Mehta, Jyotsna Kapoor, Dinesh Bhurani
Autologous stem cell transplant (ASCT) is standard consolidation therapy in management of multiple myeloma (MM) patients. We reviewed records of all consecutive MM patients who underwent ASCT with high-dose melphalan at our center from year 2002 to 2016. A total of 141 ASCT were conducted (90 males and 51 females) with median age of 55 years (23-68 years). Median time from diagnosis to transplant was 7 months (3-79), with majority of patients underwent transplant in first remission, while 17 (12%) patients received transplant beyond first remission...
May 21, 2018: Annals of Hematology
https://www.readbyqxmd.com/read/29779321/-the-value-of-serum-heavy-light-chain-immunoassay-to-assess-therapeutic-response-in-patients-with-multiple-myeloma
#14
X C Yu, W Su, J L Zhuang
Objective: To assess the value of immunoglobulin heavy/light chain (HLC) immunoassay on therapeutic response in patients with multiple myeloma(MM). Methods: A total of 45 newly diagnosed MM patients were retrospectively enrolled in Peking Union Medical College Hospital from 2013 to 2016, whose 115 serum samples were consecutively collected. HLC was tested to evaluate response and compare with other methods for M protein detection. Results: ①There were 30 males and 15 females in total of whom the monoclonal immunoglobulin was IgG in 27 (IgGκ∶IgGλ 12∶15) and IgA (IgAκ∶IgAλ 9∶9) in 18...
April 14, 2018: Zhonghua Xue Ye Xue za Zhi, Zhonghua Xueyexue Zazhi
https://www.readbyqxmd.com/read/29751116/pharmacokinetics-of-high-dose-propylene-glycol-free-melphalan-in-multiple-myeloma-patients-undergoing-autologous-hematopoietic-cell-transplantation
#15
Binod Dhakal, Anita D'Souza, Arjun Lakshman, Mehdi Hamadani, Saurabh Chhabra, Robert Thompson, Nirav Shah, Marcelo Pasquini, Paramweswaran Hari
High-dose melphalan followed by autologous stem cell transplant (ASCT) is standard of care for eligible patients with multiple myeloma (MM). Evomela (propylene glycol-free melphalan HCl [PG-Free Mel]; Spectrum Pharmaceuticals, Irvine, CA) was approved by the US Food and Drug Administration as conditioning therapy for ASCT in MM in 2 daily 100-mg/m2 doses for a total dose of 200 mg/m2 . In this phase II, open-label study PG-Free Mel (Evomela) conditioning was given at single dose of 200 mg/m2 on day -2 pre-ASCT to establish pharmacokinetic (PK) parameters and safety...
May 8, 2018: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/29729815/corrigendum-to-simplified-response-monitoring-criteria-for-multiple-myeloma-in-patients-undergoing-therapy-with-novel-agents-using-computed-tomography-eur-j-radiol-85-december-12-2016-2195-2199
#16
Christoph Schabel, Marius Horger, Sara Kum, Katja Weisel, Jan Fritz, Sorin D Ioanoviciu, Georg Bier
No abstract text is available yet for this article.
June 2018: European Journal of Radiology
https://www.readbyqxmd.com/read/29700207/representation-of-minorities-and-elderly-patients-in-multiple-myeloma-clinical-trials
#17
Narjust Duma, Tariq Azam, Irbaz Bin Riaz, Miguel Gonzalez-Velez, Sikander Ailawadhi, Ronald Go
Multiple myeloma (MM) occurs in all races, but the incidence in non-Hispanic black patients (NHBs) is two to three times higher than in non-Hispanic white patients (NHWs). We determined the representation of minorities and elderly patients in MM clinical trials. Enrollment data from all therapeutic trials reported in ClinicalTrials.gov from 2000 to 2016 were analyzed. Enrollment fraction (EF) was defined as the number of trial enrollees divided by the 2014 MM prevalence. Participation in MM clinical trials varied significantly across racial and ethnic groups; NHWs were more likely to be enrolled in clinical trials (EF 0...
April 26, 2018: Oncologist
https://www.readbyqxmd.com/read/29672885/use-of-depth-of-response-to-predict-progression-free-survival-in-relapsed-or-refractory-multiple-myeloma-evaluation-of-results-from-102-clinical-trials
#18
Naveen Mangal, Ahmed Hamed Salem, Rajeev M Menon, Kevin J Freise
Progression-free survival (PFS) is the standard endpoint for demonstration of clinical effectiveness of novel therapies in relapsed or refractory multiple myeloma (RRMM). However, the long evaluation times for PFS limits its usefulness in the development of new therapies. Therefore, the objective of this analysis was to determine the relationship between response rates and median PFS in RRMM. A database was systematically developed from 268 identified RRMM trials reported from 1999 to 2016. Evaluated covariates for the relationship between response rates and PFS included age, sex, drug class(es), and number of drug classes...
April 19, 2018: Hematological Oncology
https://www.readbyqxmd.com/read/29661050/healthcare-resource-use-and-costs-associated-with-chronic-kidney-disease-in-us-private-insurance-patients-with-multiple-myeloma
#19
Debajyoti Bhowmik, Xue Song, Michele Intorcia, Shia T Kent, Nianwen Shi
Objectives Within a median 1.2 years after patients have an initial diagnosis with multiple myeloma, up to 61% were diagnosed with renal impairment and 50% were diagnosed with chronic kidney disease. This study estimated economic burden associated with chronic kidney disease in multiple myeloma patients in the US. Methods In this retrospective cohort study, patients ≥18 years old with ≥1 inpatient or ≥ 2 outpatient multiple myeloma diagnoses between 1 January 2008 and 31 March 2015 were identified from MarketScan® Commercial and Medicare Supplemental Databases...
January 1, 2018: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/29628465/-pharmacological-characteristics-and-clinical-study-results-of-the-oral-proteasome-inhibitor-ixazomib-ninlaro-%C3%A2-capsules-2-3-mg-3-mg-and-4-mg
#20
Michiko Machida, Shinichi Fukunaga, Takahito Hara
Ixazomib (Ninlaro® capsule) is an oral small molecule 20S proteasome inhibitor created by Millennium Pharmaceuticals, Inc (Takeda Oncology Company). Ubiquitin proteasome system is a major regulatory system for maintaining protein homeostasis, and an important mechanism for degrading proteins, such as those involved in proliferation regulation, cell cycle regulation and apoptosis, in cells. Ixazomib selectively and reversibly binds to the β5 subunit of the 20S proteasome, inhibits its chymotrypsin-like activity, and thereby accumulates ubiquitinated proteins...
2018: Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica
keyword
keyword
164686
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"